PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors.
T A YapA D ChoudhuryE HamiltonL S RosenK L StrattonM S GordonD SchaerL LiuL ZhangR K MittapalliW ZhongN SomanA W Tolcher
Published in: ESMO open (2024)
Antitumor activity of PF-06952229 was observed in preclinical studies. PF-06952229 was generally well tolerated with manageable toxicity; a small group of patients achieved durable responses and/or disease stabilization.